139 related articles for article (PubMed ID: 19129278)
1. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
Perng DW; Tao CW; Su KC; Tsai CC; Liu LY; Lee YC
Eur Respir J; 2009 Apr; 33(4):778-84. PubMed ID: 19129278
[TBL] [Abstract][Full Text] [Related]
2. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
3. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
4. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
5. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
6. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Gan WQ; Rousseau R;
Am J Respir Crit Care Med; 2008 Jun; 177(11):1207-14. PubMed ID: 18310480
[TBL] [Abstract][Full Text] [Related]
7. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
[TBL] [Abstract][Full Text] [Related]
9. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J
Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
[TBL] [Abstract][Full Text] [Related]
10. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
Dalal AA; Candrilli SD; Davis KL
Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
[TBL] [Abstract][Full Text] [Related]
12. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J
Respiration; 2013; 86(4):280-7. PubMed ID: 23880883
[TBL] [Abstract][Full Text] [Related]
13. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
[TBL] [Abstract][Full Text] [Related]
14. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.
Liu Y; Shi H; Sun X; Zhang D; Zhang Y; Yang K; Mi L; Li M
Eur J Intern Med; 2014 Jun; 25(5):491-5. PubMed ID: 24816076
[TBL] [Abstract][Full Text] [Related]
15. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
Bourbeau J; Christodoulopoulos P; Maltais F; Yamauchi Y; Olivenstein R; Hamid Q
Thorax; 2007 Nov; 62(11):938-43. PubMed ID: 17557771
[TBL] [Abstract][Full Text] [Related]
16. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD.
Powrie DJ; Wilkinson TM; Donaldson GC; Jones P; Scrine K; Viel K; Kesten S; Wedzicha JA
Eur Respir J; 2007 Sep; 30(3):472-8. PubMed ID: 17504798
[TBL] [Abstract][Full Text] [Related]
17. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.
Fardon T; Haggart K; Lee DK; Lipworth BJ
Respir Med; 2007 Jun; 101(6):1218-28. PubMed ID: 17178217
[TBL] [Abstract][Full Text] [Related]
18. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
19. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
20. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
